Novartis' Afinitor performs in pancreatic cancer trial

Novartis' (NYSE:NVS) cancer drug Afinitor helps patients with pancreatic cancer live longer without tumor growth, a late-stage trial showed, giving the company a boost ahead of the biggest annual cancer meeting. Release | Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.